TDI 202

ALS is a complex disorder which the cause(s) are not entirely understood. However, scientists at the ALS Therapy Development Institute have discovered a number of immune system related aspects of the disease for which they are screening potential treatments, including this anti-sense oligoneuclueotide (ASO). 


Type: Gene Therapy
Stage: Active
Status: Active
Sponsor: ALS Therapy Development Institute

TDI Says:

ASOs are relatively new therapeutic strategies and delivery mechanisms. Early stage PK/PD experiments will be crucial to determine whether or not to continue into large scale efficacy studies.

Comment on this Topic

(All comments are moderated before they appear here.)
Combined Federal Campaign
Work for the Federal Government? Support ALS
research by joining the Combined Federal Campaign.